Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug aims to cut injection frequency for wet AMD patients

NCT ID NCT06668064

Disease control Sponsor: EyePoint Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 6 times

Summary

This phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 people with wet AMD will receive either EYP-1901 or standard aflibercept injections over 2 years. The main goal is to see if EYP-1901 can maintain or improve vision while reducing the number of injections needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EYP-1901 (a tyrosine kinase inhibitor given as an eye injection)
What this could lead to
If it works, this could mean fewer eye injections for people with wet AMD while maintaining or improving vision.
What could go wrong
This is still an experimental treatment; it may not be as effective as current standard therapy, and eye injections carry risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit. * Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1). * For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit. Exclusion Criteria: * Subfoveal fibrosis, atrophy, or scarring in the center subfield. * BCVA using ETDRS charts \<20 letters (20/400 Snellen equivalent) in the fellow eye.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WAMD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WAMD Wet age related macular degeneration

Contacts and locations

Locations

  • Advanced Research, LLC

    Deerfield Beach, Florida, 33064, United States

  • Advanced Vision Institute

    Longmont, Colorado, 80503, United States

  • American Institute of Research

    Whittier, California, 95008, United States

  • Bay Area Retina Associates

    Walnut Creek, California, 94598, United States

  • California Retina Consultants

    Bakersfield, California, 93309, United States

  • Cape Fear Retinal Associates, PC

    Wilmington, North Carolina, 28401, United States

  • Center for Retina & Macular Disease

    Winter Haven, Florida, 33880, United States

  • Charles Retina Institute

    Germantown, Tennessee, 38138, United States

  • Connecticut Eye Consultants, P.C.

    Danbury, Connecticut, 06810, United States

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland, 21740, United States

  • Deep Blue Retina Clinical Research PLLC

    Southaven, Mississippi, 38671, United States

  • Erie Retina Research

    Erie, Pennsylvania, 16507, United States

  • Eye Associates of Pinellas

    Pinellas Park, Florida, 33782, United States

  • Eye Care Specialists - Kingston Location

    Kingston, Pennsylvania, 18704, United States

  • Eye Center of Northern Colorado, PC

    Fort Collins, Colorado, 80528, United States

  • Florida Retina Consultants

    Lakeland, Florida, 33805, United States

  • Florida Retina Institute

    Orlando, Florida, 32806, United States

  • Foundation for Vision Research

    Grand Rapids, Michigan, 49546, United States

  • Gerogia Retina

    Marietta, Georgia, 30060, United States

  • Macula and Retina Institute

    Glendale, California, 91203, United States

  • Maine Eye Center

    Portland, Maine, 04101, United States

  • MedEye Associates

    South Miami, Florida, 33143, United States

  • Midwest Eye Institute

    Carmel, Indiana, 46290, United States

  • NJ Retina

    Teaneck, New Jersey, 07666, United States

  • NJ Retina

    Toms River, New Jersey, 08755, United States

  • New England Retina Consultants

    Springfield, Massachusetts, 01107, United States

  • Ophthalmic Consultants of Boston OCB - Boston

    Boston, Massachusetts, 02114, United States

  • Palmetto Retina Center

    Florence, South Carolina, 29169, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Piedmont Retina Specialists, P.A. - Winston-Salem Office

    Winston-Salem, North Carolina, 27103, United States

  • RSC Research, PLLC

    Denver, Colorado, 80210, United States

  • Retina Associates

    Elmhurst, Illinois, 60126, United States

  • Retina Associates LLC

    Lenexa, Kansas, 66215, United States

  • Retina Associates of Michigan

    Grand Blanc, Michigan, 48439, United States

  • Retina Associates of Utah

    Salt Lake City, Utah, 84107, United States

  • Retina Associates of Western NY, PC

    Rochester, New York, 14620, United States

  • Retina Associates, P.C.

    Winchester, Virginia, 22601, United States

  • Retina Consultants

    Charleston, South Carolina, 29414, United States

  • Retina Consultants PLLC

    Slingerlands, New York, 12159, United States

  • Retina Consultants San Diego

    Poway, California, 92064, United States

  • Retina Consultants of Carolina P.A

    Greenville, South Carolina, 29605, United States

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii, 96701, United States

  • Retina Consultants of Southern California

    Redlands, California, 92374, United States

  • Retina Consultants of Texas

    The Woodlands, Texas, 77384, United States

  • Retina Consultants of Texas (Retina Consultants of Houston) - Woodlands

    Bellaire, Texas, 77401, United States

  • Retina Group of New England, PC

    Waterford, Connecticut, 06385, United States

  • Retina Groups of Washington

    Chevy Chase, Maryland, 20815, United States

  • Retina Partners of Northwest Arkansas

    Springdale, Arkansas, 72764, United States

  • Retina Research Institute of Texas Integrated Clinical Research

    Abilene, Texas, 79606, United States

  • Retina Specialists

    Towson, Maryland, 21204, United States

  • Retina Specialists of Tampa

    Tampa, Florida, 33544, United States

  • Retina Specialty Institute

    Pensacola, Florida, 32503, United States

  • Retina Vitreous Associates Medical Group

    Beverly Hills, California, 90211, United States

  • Retina Vitreous Associates of Florida

    Tampa, Florida, 33617, United States

  • Retina Vitreous Surgeons of CNY, PC

    Liverpool, New York, 13088, United States

  • Retina and Vitreous of Texas

    Bellaire, Texas, 77401, United States

  • Retinal Consultants Medical Group

    Sacramento, California, 95841, United States

  • Retinal Consultants of Texas

    San Antonio, Texas, 78240, United States

  • Retinal Research Institute, LLC

    Phoenix, Arizona, 85053, United States

  • Salt Lake Retina

    West Jordan, Utah, 84088, United States

  • San Antonio Eye Center

    San Antonio, Texas, 78215, United States

  • Sierra Eye Associates

    Reno, Nevada, 89502, United States

  • SightSera Clinical Research LLC

    Greenwich, Connecticut, 06830, United States

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas, 76087, United States

  • Texas Retina Associates

    Dallas, Texas, 75231, United States

  • Texas Retina Associates

    Plano, Texas, 75075, United States

  • The Retina Care Center

    Baltimore, Maryland, 21209, United States

  • The Retina Group of Washington

    Fairfax, Virginia, 22031, United States

  • The Retina Institute

    St Louis, Missouri, 63128, United States

  • Tulsa Retina Consultant

    Tulsa, Oklahoma, 74114, United States

  • Tyler Retina Consultants

    Tyler, Texas, 75703, United States

  • University Retina and Macula Associates

    Lemont, Illinois, 60439, United States

  • University of Wisconsin School of Medicine and Public Health (UWSMPH)

    Madison, Wisconsin, 53705, United States

  • Verum Research LLC

    Eugene, Oregon, 97401, United States

  • Vision Research Center at Eye Associates of New Mexico

    Albuquerque, New Mexico, 87109, United States

  • Western Carolina Retinal Associates, PA

    Asheville, North Carolina, 28803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.